EcoDrugPlus

Tubulin Beta 2a Class Iia

Ensembl ID : ENSLACG00000011176
Gene Symbol: TUBB2A
4 Cross references
120 Possible Orthologues:

Tubulin Beta 3 Class Iii

Ensembl ID : ENSLACG00000007844
Gene Symbol: TUBB3
2 Cross references
144 Possible Orthologues:

Tubulin Beta 4b Class Ivb

Ensembl ID : ENSLACG00000004932
Gene Symbol: TUBB4B
4 Cross references
138 Possible Orthologues:

Tubulin Beta 6 Class V

Ensembl ID : ENSLACG00000004269
Gene Symbol: TUBB6
4 Cross references
141 Possible Orthologues:

Tubulin Beta Class I

Ensembl ID : ENSLACG00000014859
Gene Symbol: TUBB
4 Cross references
223 Possible Orthologues:

Tumor Protein P53

Ensembl ID : ENSLACG00000014014
Gene Symbol: TP53
4 Cross references
253 Possible Orthologues:

Type-1 Angiotensin Ii Receptor A-Like

Ensembl ID : ENSLACG00000005398
Gene Symbol: LOC102364659
3 Cross references
11 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSLACG00000009902
Gene Symbol: TYR
4 Cross references
266 Possible Orthologues:

Tyrosine 3-Monooxygenase-Like

Ensembl ID : ENSLACG00000006317
Gene Symbol: LOC102363425
2 Cross references
187 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSLACG00000006441
Gene Symbol: TIE1
4 Cross references
205 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSLACG00000005410
Gene Symbol: UTS2R
4 Cross references
58 Possible Orthologues:

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSLACG00000013719
Gene Symbol: RELA
1 Cross references
201 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).